Bevacizumab/erlotinib combined therapy associated with substantial risk of esophageal toxicity

Socinski MA. J Clin Oncol. 2012:doi:10.1200/JXO.2012.43.1866.
Source: HemOncToday.com - Category: Cancer & Oncology Source Type: news